We have gathered a team of specialists to achieve an ambitious plan of growing the company and strengthening the brand recognition to match the incredible potential of the flourishing demand.
We are a fully integrated European based medical cannabis company. Our strategic investments and partnerships will allow us to control every stage of the production path - from research, cultivation and processing to distribution. To focus on each integrated CBD stage, we’ve organized the corporate structure as of follows:
Farzad is a Physics graduate from the University of Manchester Institute of Science and Technology. He has 30 years experience working for large organizations such as JPMorgan, Goldman Sachs, Merrill Lynch, Credit Suisse and Barclays Capital specializing in derivatives pricing, risk management and regulatory reporting.
He spent 2.5 years at Otsuka pharmaceuticals Europe - A Japanese company focused on mental health advising them in Transparency, Compliance and regulatory reporting. Farzad is also a founder of Finity Asset, specializing in advising junior mining and oil & gas companies raise funding. Farzad has been responsible for the commercial development of Winchester MD (Formerly Green Biosciences).
Graduated with a major in Economics from McGill University (Montreal) Marti has over 2 years direct experience working in the UK Cannabis industry. Marti is the principal founder of Winchester MD (formerly Green Biosciences) and has been responsible for the successful growth of Winchester brands – UK’s fastest growing CBD company. Marti has implemented streamlined operational controls that have kept our costs low while expanding the UK customer base from zero to 35,000 in just 2 years. He is now applying the same principles to grow our brands in the rest of Europe.
Fraser McGee is a UK qualified solicitor and specialised in corporate finance and investment fund work with prominent City law firms before moving to work in in-house with investment banks. After working as general counsel at the globally focused hedge fund RAB Capital plc with the Special Situations, Energy and Technology Funds Fraser became the CEO of an AIM quoted natural resources business, partnering with the Majors before setting up an independent consultancy business to provide general counsel services to the alternative investment sector.
That work extended to the European medical cannabis space from the early part of 2018 and included working with networks of entrepreneurs, professional service providers and investors in the industry around the world.
Fraser is also admitted as a solicitor of the Eastern Caribbean Supreme Court and has practised as an off-shore lawyer with a BVI and Cayman Islands law firm.
VP of Product & Brand Development
An award winning, multi-talented creative director with extensive experience in brand development, product advertising and design. He is a passionate and inventive creator of innovative marketing strategies and campaigns. Seann brings a fresh and unique style to his campaigns and has been acknowledged for this through multiple industry awards.
Head of Research and Development
Andrea Rampado is a research technologist within the field of industrial applications of cavitation processes. Since 2017 Andrea hase been working in the development of new cannabis genetics and new techniques for green house cultivation. He is experienced in the construction of biomass energy plants, and has helped start several successful startups such as Biokavitus.com specialized in the treatment of water and industrial process waste. Andrea is Head of Research and Development at Wincestermd
International law firm Hill Dickinson are the leading medical cannabis law firm in the UK. The Corporate team has a strong ECM reputation and advised on the first medical cannabis investment by an AIM listed company in the UK (FastForward Innovations’ investment in Nuuvera Inc. in 2017) and in March 2018 advised Sativa Investments PLC on the first IPO of a medical cannabis company in the UK since GW Pharma in 2001.
Hill Dickinson currently advise a number of leading UK, European and North American companies, private equity groups and institutions on medical cannabis law and regulation as well as licensing and corporate opportunities in Europe.
Hill Dickinson has an award winning Health and Life Sciences team, currently acting for more than 100 independent healthcare, pharmaceutical, life-science, artificial intelligence and biotech/biomedical companies as well as over 100 NHS bodies and regulators.
Hill Dickinson’s sector knowledge combined with its relationship with public health, life sciences and regulatory bodies un the UK, ensures the Firm provides a first-class and cost-effective solution on a wide range of legal transactions and matters affecting the medical cannabis industry.
To Learn More, Reach out